Clinical

Dataset Information

0

Concordance study between Guardant360 and RASKET-B(MEBGEN) of RAS/BRAF evaluation in colorectal cancer. (GOZILA additional study).


ABSTRACT: Primary outcome(s): Overall percent agreement (OPA), positive percent agreement (PPA), and negative percent agreement (NPA) of RAS mutations by Guardant360 in comparison with those assessed by RASKET-B. OPA, PPA, NPA of BRAF V600E mutations by Guardant360 in comparison with those assessed by RASKET-B.

DISEASE(S): Patients With Unresectable Advanced/recurrent Colorectal Cancers

PROVIDER: 2724283 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Similar Datasets

2013-07-07 | E-GEOD-5481 | biostudies-arrayexpress
2013-07-07 | GSE5481 | GEO
2024-02-21 | E-MTAB-13806 | biostudies-arrayexpress
2017-01-03 | PXD004585 | Pride
2024-08-23 | E-MTAB-14298 | biostudies-arrayexpress
2023-12-20 | E-MTAB-13283 | biostudies-arrayexpress
2021-10-20 | E-MTAB-11004 | biostudies-arrayexpress
2022-01-28 | GSE194425 | GEO
2013-12-31 | E-GEOD-50678 | biostudies-arrayexpress
2013-03-07 | E-GEOD-38007 | biostudies-arrayexpress